{'fraction_non_alphanumeric': 0.031118587047939444, 'fraction_numerical': 0.01682085786375105, 'mean_word_length': 4.9798994974874375, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Factors modifying remission in cytostatic chemotherapy of squamous cell carcinoma recurrence in the area of the head and neck].

From 1981 to 1986 eighty-five patients underwent palliative chemotherapeutic treatment at the E.N.T. Department of the University Hospital in Graz. In seventy-three recurrent tumours comparable RR were achieved with ADM/CDDP as well as with MTX/5-FU. In 39 patients a second treatment after failure or relapse of previous therapy was applied, containing predominantly CDDP/BLM resulting in a RR of 18%. The tumour stage proved to be the single most important factor concerning response to treatment in first as well as second line chemotherapy. Stage IV tumours showed a significantly lower RR compared to neoplasms without large neck masses (stages II, III), the RR being 59% versus 19% (p = 0.01). Furthermore, performance status, preceding therapeutical modalities, and location of the tumours were shown to be of secondary prognostic importance. In the latter group, age and the time interval between recurrences appeared to be of no significance. To evaluate the most effective regimen, highly differentiated analysis of all available data is imperative.